Narrative review explores new immunotherapeutic strategies to improve patient outcomes in multiple sclerosis, suggesting potential advancements in personalized treatment.
Key Points
This review examines the latest immunotherapeutic strategies in managing multiple sclerosis, particularly focusing on progressive forms such as PPMS.
Narrative review of literature on multiple sclerosis pathophysiology, diagnostic challenges, and new treatments.
Analysis of both preclinical and clinical evidence regarding various therapeutic agents including biologics and remyelination methods.
Evaluation of advanced imaging techniques and biomarker development for personalized treatment.
Anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab) effectively reduce disease activity and slow progression in PPMS.
Bruton’s tyrosine kinase inhibitors show promise in meeting unmet medical needs for MS patients.
Enhanced imaging and biomarkers improve disease monitoring and patient outcomes, enabling more tailored therapies.